jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Jan. 06, 2021

Feb. 05, 2025

jRCT2031200286

ONO-4578-04:Phase 1 study of ONO-4578 given as combinations of ONO-4578, ONO-4538 and modified FOLFIRINOX or Gem/nab-PTX in subjects with metastatic pancreatic cancer(ONO-4578-04)

ONO-4578-04:ONO-4578 Phase 1 Study

Namba Yoshinobu

Ono Pharmaceutical Co.,LTD

3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan

+81-120-626-190

clinical_trial@ono-pharma.com

Center Information Medical

Ono Pharmaceutical Co.,LTD

3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan

+81-120-626-190

clinical_trial@ono-pharma.com

Complete

Jan. 16, 2021

Jan. 13, 2021
60

Interventional

non-randomized controlled trial

open(masking not used)

uncontrolled control

single assignment

treatment purpose

1. Pancreatic invasive ducatal adenocarcinoma
2. Life expectancy of at least 3 months
3. Patients with ECOG performance status 0 or 1

1. Patients with severe complication
2. Patients with multiple primary cancers

20age old over
No limit

Both

metastatic pancreatic cancer

ONO-4578 given as combinations of ONO-4578, ONO-4538 and modified FOLFIRINOX or Gem/nab-PTX

Safety, tolerability

Ono Pharmaceutical Co.,LTD
Kanagawa Cancer Center Institutional Review Board
2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa

+81-45-520-2222

Approval

Dec. 28, 2020

No

NCT06538207

none

History of Changes

No Publication date
10 Feb. 05, 2025 (this page) Changes
9 Nov. 15, 2024 Detail Changes
8 Sept. 29, 2024 Detail Changes
7 Sept. 04, 2024 Detail Changes
6 Mar. 03, 2023 Detail Changes
5 Oct. 07, 2022 Detail Changes
4 Feb. 10, 2022 Detail Changes
3 July. 16, 2021 Detail Changes
2 Mar. 30, 2021 Detail Changes
1 Jan. 06, 2021 Detail